Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer

Epigenetics

Volumn 11, Issue 12, 2016, Pages 845-857

  Greville, Gordon ^a   McCann, Amanda ^b,c   Rudd, Pauline M ^a   Saldova, Radka ^a  

^a NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Chemo resistance; epigenetic therapies; epigenetics; hypoxia; N glycosylation

Indexed keywords

AZACITIDINE; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA METHYLTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETHIONINE ADENOSYLTRANSFERASE 2A; FUCOSYLTRANSFERASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MANNOSYL (ALPHA 1,6) GLYCOPROTEIN BETA 1,6 N ACETYL GLUCOSAMINYLTRANSFERASE; N ACETYLGLUCOSAMINE; N ACETYLNEURAMINIC ACID; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; UVOMORULIN; ENZYME INHIBITOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FUCOSYLATION; GENE MUTATION; GLYCOSYLATION; HUMAN; HYPOXIA; NONHUMAN; OVARY CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SIALYLATION; SURVIVAL RATE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; OVARIAN NEOPLASMS; PATHOLOGY;

BREAST NEOPLASMS; DNA MODIFICATION METHYLASES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION; HUMANS; OVARIAN NEOPLASMS;

EID: 85008256628     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.1080/15592294.2016.1241932     Document Type: Review

References (131)

1. IARC. Globocan 2012. Lyon:2014. [accessed 2015 Jan 27]. globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
2. IARC CRUK. World Cancer Factsheet. London:2014. [accessed 2015 Jan 27]. http://publications.cancerresearchuk.org/downloads/Product/CS_REPORT_WORLD.pdf.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797):747-52; PMID:10963602; http://dx.doi.org/10.1038/35021093
4. Chikarmane S, Tirumani S, Howard S, Jagannathan J, DiPiro P. Metastatic patterns of breast cancer subtypes:What radiologists should know in the era of personalized cancer medicine. Clin Radiol 2015. 70(1):1-10; PMID:25300558; http://dx.doi.org/10.1016/j.crad.2014.08.015
5. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran Pathologic Basis of Disease, Professional Edition:Expert Consult-Online:Elsevier Health Sciences; 2009
6. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer control:journal of the moffitt cancer center. 2010; 17(3):173-6; PMID:20664514
7. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121(7):2750; PMID:21633166; http://dx.doi.org/10.1172/JCI45014
8. Jiao Q, Wu A, Shao G, Peng H, Wang M, Ji S, Liu P, Zhang J. The latest progress in research on triple negative breast cancer (TNBC):risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis 2014; 6(9):1329-35; PMID:25276378; http://dx.doi.org/10.3978/j.issn.2072-1439.2014.08.13
9. dos Anjos Pultz B, da Luz FAC, de Faria PR, Oliveira APL, de Araújo RA, Silva MJB. Far beyond the usual biomarkers in breast cancer:a review. J Cancer 2014; 5(7):559; PMID:25057307; http://dx.doi.org/10.7150/jca.8925
10. Drukteinis JS, Mooney BP, Flowers CI, Gatenby RA. Beyond Mammography:New frontiers in breast cancer screening. Am J Med 2013; 126(6):472-9; PMID:23561631; http://dx.doi.org/10.1016/j.amjmed.2012.11.025
11. Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E. Breast density as a predictor of mammographic detection:comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000; 92(13):1081-7; PMID:10880551; http://dx.doi.org/10.1093/jnci/92.13.1081
12. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Eng J Med 2012; 367(21):1998-2005; PMID:23171096; http://dx.doi.org/10.1056/NEJMoa1206809
13. Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss medical board. N Eng J Med 2014; 370(21):1965-7; PMID:24738641; http://dx.doi.org/10.1056/NEJMp1401875
14. Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law WL, et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 2013; 8(1):3; PMID:23301032; http://dx.doi.org/10.1371/journal.pone.0053141
15. Pedersen AC, Sørensen PD, Jacobsen EH, Madsen JS, Brandslund I. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clin Chem Lab Med 2013; 51(7):1511-9; PMID:23403727; http://dx.doi.org/10.1515/cclm-2012-0488
16. Pierce A, Saldova R, Abd Hamid UM, Abrahams JL, McDermott EW, Evoy D, Duffy MJ, Rudd PM. Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients. Glycobiology 2010; 20(10):1283-8; PMID:20581008; http://dx.doi.org/10.1093/glycob/cwq090
17. Abd Hamid UM, Royle L, Saldova R, Radcliffe CM, Harvey DJ, Storr SJ, Pardo M, Antrobus R, Chapman CJ, Zitzmann N, et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008; 18(12):1105-18; PMID:18818422; http://dx.doi.org/10.1093/glycob/cwn095
18. SEER. SEER Stat Fact Sheets:Ovary Cancer 2014. NIH [accessed 2015 Jan 27]. Available from:http://seer.cancer.gov/statfacts/html/ovary.html
19. Society AC. Ovarian Cancer:American Cancer Society; 2015 [updated 2015 May 8, cited 2015 Nov 4]. Available from:http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-survival-rates
20. Thalhammer T, Mungenast F. Estrogen biosynthesis and action in ovarian cancer. Frontiers Endocrinol 2014; 5:192; PMID:25429284; http://dx.doi.org/10.3389/fendo.2014.00192
21. Patel S, Kumar L, Singh N. Metformin and epithelial ovarian cancer therapeutics. Cell Oncol 2015; 38(5):365-75; PMID:26266765; http://dx.doi.org/10.1007/s13402-015-0235-7
22. DeSantis C, Siegel R, Jemal A. Breast cancer facts and figures Atlanta:American Cancer Society, Inc. 2013–2014. Atlanta:American Cancer Society, Inc. 2013
23. Tarver T. Cancer Facts & Figures 2012. American Cancer Society (ACS) Atlanta, GA:American Cancer Society, 2012. [accessed 2015 Jan 27]. http://uacc.arizona.edu/sites/default/files/acs_2012.pdf
24. Cohen JG, White M, Cruz A, Farias-Eisner R. In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem 2014; 5(3):286-300; PMID:25225597; http://dx.doi.org/10.4331/wjbc.v5.i3.286
25. Bowtell DDL. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010; 10(11):803-8; PMID:20944665; http://dx.doi.org/10.1038/nrc2946
26. Shih IM, Kurman RJ. Ovarian Tumorigenesis:A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164(5):1511-8; PMID:15111296; http://dx.doi.org/10.1016/S0002-9440(10)63708-X
27. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm. Hum Pathol 2011; 42(7):918-31; PMID:21683865; http://dx.doi.org/10.1016/j.humpath.2011.03.003
28. Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol 2003; 90(1):75-82; PMID:12821345; http://dx.doi.org/10.1016/S0090-8258(03)00175-6
29. Liang D, Ma Y, Liu J, Trope C, Holm R, Nesland J, Suo Z. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 2012; 12(1):201; PMID:22642602; http://dx.doi.org/10.1186/1471-2407-12-201
30. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci 2012; 109(8):2784-9; PMID:22308314; http://dx.doi.org/10.1073/pnas.1018866109
31. O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MHZ, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, et al. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin 2015; 3:257-75; PMID:26676166; http://dx.doi.org/10.1016/j.bbacli.2015.03.003
32. Jacot W, Theillet C, Guiu S, Lamy PJ. Targeting triple-negative breast cancer and high-grade ovarian carcinoma:refining BRCAness beyond BRCA1/2 mutations? Future Oncol 2015; 11(4):557-9; PMID:25686112; http://dx.doi.org/10.2217/fon.14.268
33. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, et al. Association between brca1 and brca2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012; 307(4):382-9; PMID:22274685; http://dx.doi.org/10.1001/jama.2012.20
34. Llop E, Ferrer-Batallé M, Barrabés S, Guerrero PE, Ramírez M, Saldova R, Rudd PM, Aleixandre RN, Comet J, de Llorens R, et al. Improvement of prostate cancer diagnosis by detecting PSA glycosylation-specific changes. Theranostics. 2016; 6(8):1190-204; PMID:27279911; http://dx.doi.org/10.7150/thno.15226
35. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tanaka J, Kagebayashi C, Satomura S. High-sensitivity Lens culinaris agglutinin-reactive α-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol 2014; 49(3):555-63; PMID:24057163; http://dx.doi.org/10.1007/s00535-013-0883-1
36. Agrawal P, Kurcon T, Pilobello KT, Rakus JF, Koppolu S, Liu Z, Batista BS, Eng WS, Hsu KL, Liang Y, et al. Mapping posttranscriptional regulation of the human glycome uncovers microRNA defining the glycocode. Proc Natl Acad Sci U S A 2014; 111(11):4338-43; PMID:24591635; http://dx.doi.org/10.1073/pnas.1321524111
37. Li S, Payne S, Wang F, Claus P, Su Z, Groth J, Geradts J, de Ridder G, Alvarez R, Marcom PK, et al. Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance. Breast Cancer Res 2015; 17(1):1-16; PMID:26141457; http://dx.doi.org/10.1186/s13058-014-0509-4
38. Watson JA, Watson CJ, McCrohan AM, Woodfine K, Tosetto M, McDaid J, Gallagher E, Betts D, Baugh J, O'Sullivan J, et al. Generation of an epigenetic signature by chronic hypoxia in prostate cells. Hum Mol Genetics 2009; 18(19):3594-604; PMID:19584087; http://dx.doi.org/10.1093/hmg/ddp307
39. Larkin A, Chang MM, Whitworth GE, Imperiali B. Biochemical evidence for an alternate pathway in N-linked glycoprotein biosynthesis. Nat Chem Biol 2013; 9(6):367-73; PMID:23624439; http://dx.doi.org/10.1038/nchembio.1249
40. Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, Panico M, Morris HR, Dell A, Wren BW, et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 2002; 298(5599):1790-3; PMID:12459590; http://dx.doi.org/10.1126/science.298.5599.1790
41. Valderrama-Rincon JD, Fisher AC, Merritt JH, Fan YY, Reading CA, Chhiba K, Heiss C, Azadi P, Aebi M, DeLisa MP. An engineered eukaryotic protein glycosylation pathway in Escherichia coli. Nat Chem Biol 2012; 8(5):434-6; PMID:22446837; http://dx.doi.org/10.1038/nchembio.921
42. Bill RM, Revers L, Wilson I. Protein Glycosylation:Springer Science & Business Media; 2012
43. Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol 2008; 8(11):874-87; PMID:18846099; http://dx.doi.org/10.1038/nri2417
44. Hakomori SI. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. In:George FVW, George K, editors. Advances in cancer research:Academic Press; 1989; 52:p. 257-331.
45. Drake RR, Jones EE, Powers TW, Nyalwidhe JO. Chapter Ten - altered glycosylation in prostate cancer. In:Richard RD, Lauren EB, editors. Advances in Cancer Research:Academic Press; 2015; 126:p. 345-82.
46. Saldova R, Reuben JM, Abd Hamid UM, Rudd PM, Cristofanilli M. Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. Ann Oncol 2011; 22(5):1113-9; PMID:21127012; http://dx.doi.org/10.1093/annonc/mdq570
47. Reticker-Flynn NE, Bhatia SN. Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche. Cancer Discov 2015; 5(2):168-81; PMID:25421439; http://dx.doi.org/10.1158/2159-8290.CD-13-0760
48. Saldova R, Dempsey E, Perez-Garay M, Marino K, Watson JA, Blanco-Fernandez A, Struwe WB, Harvey DJ, Madden SF, Peracaula R, et al. 5-AZA-2′-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer. Epigenetics 2011; 6(11):1362-72; PMID:22086115; http://dx.doi.org/10.4161/epi.6.11.17977
49. Ashkani J, Naidoo KJ. Glycosyltransferase gene expression profiles classify cancer types and propose prognostic subtypes. Scientific Reports 2016; 6:26451; PMID:27198045; http://dx.doi.org/10.1038/srep26451
50. Potapenko IO, Luders T, Russnes HG, Helland A, Sorlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD. Glycan-related gene expression signatures in breast cancer subtypes; relation to survival. Mol Oncol 2015; 9(4):861-76; PMID:25655580; http://dx.doi.org/10.1016/j.molonc.2014.12.013
51. Potapenko IO, Haakensen VD, Luders T, Helland A, Bukholm I, Sorlie T, Kristensen VN, Lingjaerde OC, Børresen-Dale AL. Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol 2010; 4(2):98-118; PMID:20060370; http://dx.doi.org/10.1016/j.molonc.2009.12.001
52. Mehta A, Norton P, Liang H, Comunale MA, Wang M, Rodemich-Betesh L, Koszycki A, Noda K, Miyoshi E, Block T. Increased levels of tetra-antennary N-linked glycan but not core fucosylation are associated with hepatocellular carcinoma tissue. Cancer Epidemiol Biomarkers Prev 2012; 21(6):925-33; PMID:22490318; http://dx.doi.org/10.1158/1055-9965.EPI-11-1183
53. Alley WR, Jr, Vasseur JA, Goetz JA, Svoboda M, Mann BF, Matei DE, Menning N, Hussein A, Mechref Y, Novotny MV. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res 2012; 11(4):2282-300; PMID:22304416; http://dx.doi.org/10.1021/pr201070k
54. Huang WR, Fan XX, Tang X. SiRNA targeting EGFR effectively prevents posterior capsular opacification after cataract surgery. Mol Vision 2011; 17:2349-55; PMID:21921987
55. Nangia-Makker P, Balan V, Raz A. Galectin-3-binding and metastasis. Methods Mol Biol 2012; 878:251-66; PMID:22674139; http://dx.doi.org/10.1007/978-1-61779-854-2_17
56. Lin TW, Chang HT, Chen CH, Chen CH, Lin SW, Hsu TL, Wong CH. Galectin-3 binding protein and Galectin-1 interaction in breast cancer cell aggregation and metastasis. J Am Chem Soc 2015; 137(30):9685-93; PMID:26168351; http://dx.doi.org/10.1021/jacs.5b04744
57. Hossein G, Keshavarz M, Ahmadi S, Naderi N. Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of Galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev 2013; 14(12):7561-8; PMID:24460334; http://dx.doi.org/10.7314/APJCP.2013.14.12.7561
58. Miwa HE, Song Y, Alvarez R, Cummings RD, Stanley P. The bisecting GlcNAc in cell growth control and tumor progression. Glycoconj J 2012; 29(8-9):609-18; PMID:22476631; http://dx.doi.org/10.1007/s10719-012-9373-6
59. Pinho SS, Figueiredo J, Cabral J, Carvalho S, Dourado J, Magalhaes A, Gärtner F, Mendonfa AM, Isaji T, Gu J, et al. E-cadherin and adherens-junctions stability in gastric carcinoma:functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim Biophys Acta 2013; 3(700):2690-700; PMID:23671930; http://dx.doi.org/10.1016/j.bbagen.2012.10.021
60. Varki A, Schauer R. Sialic acids. In Varki A, Cummings RD, Esko JD, et al., editors. Cold Spring Harbor (NY):Cold Spring Harbor Laboratory Press; 2009. Chapter 14.
61. Higai K, Suzuki C, Imaizumi Y, Xin X, Azuma Y, Matsumoto K. Binding affinities of NKG2D and CD94 to sialyl Lewis X-expressing N-glycans and heparin. Biol Pharmaceutical Bulletin 2011; 34(1):8-12; PMID:21212510; http://dx.doi.org/10.1248/bpb.34.8
62. Büll C, Stoel MA, den Brok MH, Adema GJ. Sialic acids sweeten a tumor's life. Cancer Res 2014; 74(12):3199-204; PMID:24830719; http://dx.doi.org/10.1158/0008-5472.CAN-14-0728
63. Pinho SS, Reis CA. Glycosylation in cancer:mechanisms and clinical implications. Nat Rev Cancer 2015; 15(9):540-55; PMID:26289314; http://dx.doi.org/10.1038/nrc3982
64. Barthel SR, Wiese GK, Cho J, Opperman MJ, Hays DL, Siddiqui J, Pienta KJ, Furie B, Dimitroff CJ. Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci U S A 2009; 106(46):19491-6; PMID:19889975; http://dx.doi.org/10.1073/pnas.0906074106
65. Saldova R, Wormald MR, Dwek RA, Rudd PM. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers 2008; 25(4-5):219-32; PMID:19126966; http://dx.doi.org/10.1155/2008/601583
66. Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, et al. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res 2011; 71(24):7683-93; PMID:22025563; http://dx.doi.org/10.1158/0008-5472.CAN-11-1139
67. Burdick MM, McCaffery JM, Kim YS, Bochner BS, Konstantopoulos K. Colon carcinoma cell glycolipids, integrins, and other glycoproteins mediate adhesion to HUVECs under flow. Am J Physiol Cell Physiol 2003; 284(4):C977-87; PMID:12477667; http://dx.doi.org/10.1152/ajpcell.00423.2002
68. Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Demoulins T, Christoph S, Marc W, Robert EH, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest 2014; 124(4):1810-20; PMID:24569453; http://dx.doi.org/10.1172/JCI65899
69. Becker DJ, Lowe JB. Fucose:biosynthesis and biological function in mammals. Glycobiology 2003; 13(7):41R-53R; PMID:12651883; http://dx.doi.org/10.1093/glycob/cwg054
70. Wang X, Inoue S, Gu J, Miyoshi E, Noda K, Li W, Mizuno-Horikawa Y, Nakano M, Asahi M, Takahashi M, et al. Dysregulation of TGF-β1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci USA 2005; 102(44):15791-6; PMID:16236725; http://dx.doi.org/10.1073/pnas.0507375102
71. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278(5):3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200
72. Luhn K, Wild MK. Human deficiencies of fucosylation and sialylation affecting selectin ligands. Semin Immunopathol 2012; 34(3):383-99; PMID:22461019; http://dx.doi.org/10.1007/s00281-012-0304-1
73. Barthel SR, Wiese GK, Cho J, Opperman MJ, Hays DL, Siddiqui J, Pienta KJ, Furie B, Dimitroff CJ. Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci U S A 2009; 106(46):19491-6; PMID:19889975; http://dx.doi.org/10.1073/pnas.0906074106
74. Desiderio V, Papagerakis P, Tirino V, Zheng L, Matossian M, Prince ME, Paino F, Mele L, Papaccio F, Montella R, et al. Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells. Oncotarget 2015; 6(1):71-84; PMID:25428916
75. Martín-Satué M, Castellarnau CD, Blanco J. Overexpression of α(1,3)-fucosyltransferase VII is sufficient for the acquisition of lung colonization phenotype in human lung adenocarcinoma HAL-24Luc cells. Br J Cancer 1999; 80(8):1169-74; PMID:10376968; http://dx.doi.org/10.1038/sj.bjc.6690482
76. Wang X, Gu J, Ihara H, Miyoshi E, Honke K, Taniguchi N. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem 2006; 281(5):2572-7; PMID:16316986; http://dx.doi.org/10.1074/jbc.M510893200
77. Zhao Y, Itoh S, Wang X, Isaji T, Miyoshi E, Kariya Y, Miyazaki K, Kawasaki N, Taniguchi N, Gu J. Deletion of core fucosylation on alpha3beta1 integrin down-regulates its functions. J Biol Chem 2006; 281(50):38343-50; PMID:17043354; http://dx.doi.org/10.1074/jbc.M608764200
78. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y, Nagataki S. Early recognition of Hepatocellular carcinoma based on altered profiles of Alpha-Fetoprotein. N Eng J Med 1993; 328(25):1802-6; PMID:7684823; http://dx.doi.org/10.1056/NEJM199306243282502
79. Kurebayashi J, Nomura T, Hirono M, Okubo S, Udagawa K, Shiiki S, Ikeda M, Nakashima K, Tanaka K, Sonoo H. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients. Jpn J Clin Oncol 2006; 36(3):150-3; PMID:16520359; http://dx.doi.org/10.1093/jjco/hyi235
80. Merry CR, Forrest ME, Sabers JN, Beard L, Gao X-H, Hatzoglou M, Jackson MW, Wang Z, Markowitz SD, Khalil AM. DNMT1-associated long non-coding RNAs regulate global gene expression and DNA methylation in colon cancer. Hum Mol Genetics 2015; 24(21):6240-53; PMID:26307088; http://dx.doi.org/10.1093/hmg/ddv343
81. Weake V. Histone ubiquitylation control of gene expression. In:Workman JL, Abmayr SM, editors. Fundamentals of Chromatin:Springer New York; 2014:p. 257-307.
82. Johnson C, Warmoes MO, Shen X, Locasale JW. Epigenetics and cancer metabolism. Cancer Letters 2015; 356(2):309-14; PMID:24125862; http://dx.doi.org/10.1016/j.canlet.2013.09.043
83. Sandoval J, Esteller M. Cancer epigenomics:beyond genomics. Curr Opin Genetics Dev 2012; 22(1):50-5; PMID:22402447; http://dx.doi.org/10.1016/j.gde.2012.02.008
84. Gros C, Fahy J, Halby L, Dufau I, Erdmann A, Gregoire JM, Ausseil F, Vispé S, Arimondo PB. DNA methylation inhibitors in cancer:Recent and future approaches. Biochimie 2012; 94(11):2280-96; PMID:22967704; http://dx.doi.org/10.1016/j.biochi.2012.07.025
85. ClinicalTrials 2015. NIH [accessed 2015 mar 9]. Available from:https://clinicaltrials.gov/ct2/results?term=decitabine+breast&Search=Search
86. Ari F, Napieralski R, Ulukaya E, Dere E, Colling C, Honert K, Krüger A, Kiechle M, Schmitt M. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline‐based chemotherapy and the demethylating agent decitabine. Cell Biochem Function 2011; 29(8):651-9; PMID:21887697; http://dx.doi.org/10.1002/cbf.1801
87. Horvat T, Deželjin M, Redžić I, Barišić D, Herak Bosnar M, Lauc G, Zoldos V. Reversibility of membrane N-Glycome of HeLa cells upon treatment with epigenetic inhibitors. PLoS One 2013; 8(1):e54672; PMID:23336012; http://dx.doi.org/10.1371/journal.pone.0054672
88. Lauc G, Krištić J, Zoldoš V. Glycans–the third revolution in evolution. Frontiers Genetics 2014; 5:145; PMID:24904645; http://dx.doi.org/10.3389/fgene.2014.00145
89. Chakraborty AK, de Frietas Sousa J, Chakraborty D, Funasaka Y, Bhattacharya M, Chatterjee A, Pawelek J. GnT-V expression and metastatic phenotypes in macrophage–melanoma fusion hybrids is down-regulated by 5-Aza-dC:Evidence for methylation sensitive, extragenic regulation of GnT-V transcription. Gene 2006; 374(0):166-73; PMID:16556489; http://dx.doi.org/10.1016/j.gene.2006.01.031
90. Chachadi VB, Cheng H, Klinkebiel D, Christman JK, Cheng PW. 5-Aza-2′-deoxycytidine increases sialyl Lewis X on MUC1 by stimulating β-galactoside:α2,3-sialyltransferase 6 gene. Int J Biochem Cell Biol 2011; 43(4):586-93; PMID:21168523; http://dx.doi.org/10.1016/j.biocel.2010.12.015
91. Weiner-Gorzel K, Dempsey E, Milewska M, McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A, Sharpe D, et al. Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Med 2015; 4(5):745-58; PMID:25684390; http://dx.doi.org/10.1002/cam4.409
92. Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, et al. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene 2016; 35(17):2186-96; PMID:26212011; http://dx.doi.org/10.1038/onc.2015.279
93. Lesniak D, Sabri S, Xu Y, Graham K, Bhatnagar P, Suresh M, Abdulkarim B. Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer. 2013; 8(8):e71987; PMID:23991019, http://dx.doi.org/10.1371/journal.pone.0071987
94. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. b1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res 2011; 13:R84; PMID:21884573; http://dx.doi.org/10.1186/bcr2936
95. Schultz MJ, Swindall AF, Wright JW, Sztul ES, Landen CN, Bellis SL. ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. J Ovarian Res 2013; 6(1):25; PMID:23578204; http://dx.doi.org/10.1186/1757-2215-6-25
96. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006; 12(5):1507-14; PMID:16533775; http://dx.doi.org/10.1158/1078-0432.CCR-05-2049
97. Meixensberger J, Dings J, Kuhnigk H, Roosen K. Studies of tissue PO2 in normal and pathological human brain cortex. Acta Neurochir Suppl 1993; 59:58-63; PMID:7906079
98. Hancock RL, Dunne K, Walport LJ, Flashman E, Kawamura A. Epigenetic regulation by histone demethylases in hypoxia. Epigenomics 2015; 7(5):791-811; PMID:25832587; http://dx.doi.org/10.2217/epi.51.24
99. Kieda C, El Hafny-Rahbi B, Collet G, Lamerant-Fayel N, Grillon C, Guichard A, Dulak J, Jozkowicz A, Kotlinowski J, Fylaktakidou KC, et al. Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. J Mol Med 2013; 91(7):883-99; PMID:23471434; http://dx.doi.org/10.1007/s00109-013-0992-6
100. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62(12):3387-94; PMID:12067980
101. Collet G, Lamerant-Fayel N, Tertil M, El Hafny-Rahbi B, Stepniewski J, Guichard A, Foucault-Collet A, Klimkiewicz K, Petoud S, Matejuk A, et al. Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Mol Cancer Ther 2014; 13(1):165-78; PMID:24170768; http://dx.doi.org/10.1158/1535-7163.MCT-13-0637
102. Watson JA, Watson CJ, McCann A, Baugh J. Epigenetics:The epicenter of the hypoxic response. Epigenetics 2010; 5(4):293-6; PMID:20418669; http://dx.doi.org/10.4161/epi.5.4.11684
103. Shahrzad S, Bertrand K, Minhas K, Coomber BL. Induction of DNA hypomethylation by tumor hypoxia. Epigenetics 2007; 2(2):119-25; PMID:17965619; http://dx.doi.org/10.4161/epi.2.2.4613
104. Lo TF, Tsai WC, Chen ST. MicroRNA-21-3p, a Berberine-Induced miRNA, Directly Down-Regulates Human Methionine Adenosyltransferases 2A and 2B and inhibits hepatoma cell growth. PLoS One 2013; 8(9):e75628; PMID:24098708; http://dx.doi.org/10.1371/journal.pone.0075628
105. Mato JM, Lu SC. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology 2007; 45(5):1306-12; PMID:17464973; http://dx.doi.org/10.1002/hep.21650
106. Liu Q, Liu L, Zhao Y, Zhang J, Wang D, Chen J, He Y, Wu J, Zhang Z, Liu Z. Hypoxia induces genomic DNA demethylation through the activation of HIF-1alpha and transcriptional upregulation of MAT2A in hepatoma cells. Mol Cancer Ther 2011; 10(6):1113-23; PMID:21460102; http://dx.doi.org/10.1158/1535-7163.MCT-10-1010
107. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, et al. A microRNA signature of hypoxia. Mol Cell Biol 2007; 27(5):1859-67; PMID:17194750; http://dx.doi.org/10.1128/MCB.01395-06
108. Ying Q, Liang L, Guo W, Zha R, Tian Q, Huang S, Yao J, Ding J, Bao M, Ge C, et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology 2011; 54(6):2064-75; PMID:22144109; http://dx.doi.org/10.1002/hep.24614
109. Sauermann M, Sahin O, Sultmann H, Hahne F, Blaszkiewicz S, Majety M, Zatloukal K, Füzesi L, Poustka A, Wiemann S, et al. Reduced expression of vacuole membrane protein 1 affects the invasion capacity of tumor cells. Oncogene 2008; 27(9):1320-6; PMID:17724469; http://dx.doi.org/10.1038/sj.onc.1210743
110. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Chandrashekhar YS, Hall JL, Roy S, Zeng Y, et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest 2010; 120(11):4141-54; PMID:20972335; http://dx.doi.org/10.1172/JCI42980
111. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, Kung HF, Lai L, Jiang BH. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 2011; 6(4):0019139; PMID:21544242; http://dx.doi.org/10.1371/journal.pone.0019139
112. Chan YC, Khanna S, Roy S, Sen CK. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem 2011; 286(3):2047-56; PMID:21081489; http://dx.doi.org/10.1074/jbc.M110.158790
113. Koike T, Kimura N, Miyazaki K, Yabuta T, Kumamoto K, Takenoshita S, Chen J, Kobayashi M, Hosokawa M, Taniguchi A, et al. Hypoxia induces adhesion molecules on cancer cells:A missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U S A 2004; 101(21):8132-7; PMID:15141079; http://dx.doi.org/10.1073/pnas.0402088101
114. Kannagi R, Sakuma K, Miyazaki K, Lim KT, Yusa A, Yin J, Izawa M. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia:Clues in the ongoing search for new tumor markers. Cancer Sci 2010; 101(3):586-93; PMID:20085584; http://dx.doi.org/10.1111/j.1349-7006.2009.01455.x
115. Yin J, Hashimoto A, Izawa M, Miyazaki K, Chen GY, Takematsu H, Kozutsumi Y, Suzuki A, Furuhata K, Cheng FL, et al. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res 2006; 66(6):2937-45; PMID:16540641; http://dx.doi.org/10.1158/0008-5472.CAN-05-2615
116. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002; 277(26):23111-5; PMID:11943784; http://dx.doi.org/10.1074/jbc.M202487200
117. Gornik O, Wagner J, Pucic M, Knezevic A, Redzic I, Lauc G. Stability of N-glycan profiles in human plasma. Glycobiology 2009; 19(12):1547-53; PMID:19726492; http://dx.doi.org/10.1093/glycob/cwp134
118. Lauc G, Krištić J, Zoldoš V. Glycans–the third revolution in evolution. Frontiers Genetics 2014; 5:145; PMID:24904645; http://dx.doi.org/10.3389/fgene.2014.00145
119. Reymond N, d'Agua BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer 2013; 13(12):858-70; PMID:24263189; http://dx.doi.org/10.1038/nrc3628
120. Zoldoš V, Horvat T, Lauc G. Glycomics meets genomics, epigenomics and other high throughput omics for system biology studies. Curr Opin Chem Biol 2013; 17(1):34-40; PMID:23287290; http://dx.doi.org/10.1016/j.cbpa.2012.12.007
121. Lauc G, Huffman JE, Pučić M, Zgaga L, Adamczyk B, Mužinić A, Novokmet M, Polašek O, Gornik O, Krištić J, et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. 2013; 9(1):e1003225; PMID:23382691; http://dx.doi.org/10.1371/journal.pgen.1003225
122. Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B, Rudd PM, Børresen-Dale AL, Yakhini Z. Serum N-glycan analysis in breast cancer patients–Relation to tumour biology and clinical outcome. Mol Oncol 2016; 10(1):59-72; PMID:26321095; http://dx.doi.org/10.1016/j.molonc.2015.08.002.
123. ClinicalTrials.gov Ovarian 2015. NIH [accessed 2015 Sep 26] Available from:https://clinicaltrials.gov/ct2/results?term=decitabine+ovarian&Search=Search
124. Breast cancer clinicals Trials with Decitabine 2015. NIH. [accessed 2015 Sep 26] Available from:https://clinicaltrials.gov/ct2/results?term=decitabine+breast&Search=Search
125. Vasconcelos-Dos-Santos A, Oliveira IA, Lucena MC, Mantuano NR, Whelan SA, Dias WB, Todeschini AR. Biosynthetic machinery involved in aberrant glycosylation:Promising targets for developing of drugs against cancer. Front Oncol 2015; 5:138; PMID:26161361; http://dx.doi.org/10.3389/fonc.2015.00138
126. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al. A Functional genetic approach identifies the PI3K pathway as a major determinant of Trastuzumab resistance in breast cancer. Cancer Cell 2007; 12(4):395-402; PMID:17936563; http://dx.doi.org/10.1016/j.ccr.2007.08.030
127. Abdullah LN, Chow EK-H. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013; 2:3; PMID:23369605; http://dx.doi.org/10.1186/2001-1326-2-3
128. Ween MP, Armstrong MA, Oehler MK, Ricciardelli C. The role of ABC transporters in ovarian cancer progression and chemoresistance. Critical Rev Oncology/Hematol 2015; 96(2):220-56; PMID:26100653; http://dx.doi.org/10.1016/j.critrevonc.2015.05.012
129. Borley J, Brown R. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Ann Med 2015; 47(5):359-69; PMID:26158617; http://dx.doi.org/10.3109/07853890.2015.1043140
130. Ren J, Chen Y, Song H, Chen L, Wang R. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem 2013; 114(6):1395-403; PMID:23255418; http://dx.doi.org/10.1002/jcb.24481
131. Houghton JA, Houghton PJ. Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. Eur J Cancer Clin Oncol 1983; 19(6):807-15; PMID:6191988; http://dx.doi.org/10.1016/0277-5379(83)90013-5